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Among eight human bladder cancer cell lines we examined, only T24 cells were resistant to the growth inhibition effect of genistein,
an isoflavone and potent anticancer drug. Since the T24 cell line was the only cell line known to overexpress oncogenic H-Ras
val 12,
we investigated the role of H-Ras
val 12 in mediating drug resistance. Herein, we demonstrate that the phenotype of T24 cells could be
dramatically reversed and became relatively susceptible to growth inhibition by genistein if the synthesis of H-Ras
val 12 or its
downstream effector c-Fos had been suppressed. The inhibition of Ras-mediated signalling with protein kinase inhibitors, such as
PD58059 and U0126 which inhibited MEK and ERK, in T24 cells also rendered the identical phenotypic reversion. However, this
reversion was not observed when an inhibitor was used to suppress the protein phosphorylation function of PI3K or PKC. These
results suggest that the signal mediated by H-Ras
val 12 is predominantly responsible for the resistance of the cells to the anticancer
drug genistein.
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The oncoprotein Ras, a 21kDa guanine nucleotide-binding
protein, is encoded by a member (Harvey-, Kirsten-, and Neural-
ras) of the ras proto-oncogene family (Rayter et al, 1989; Maculuso
et al, 2002). Ras transduces signals in discrete intracellular
pathways (Marshall, 1995), with the route via raf-1, MEK, ERK,
and finally to induce the expression of the immediate early gene c-
fos for turning on a cascade of downstream genes as the most
prominent pathway in regulating vital cellular processes (Rayter
et al, 1989; Thorburn and Thorburn, 1994; Maculuso et al, 2002).
Mutational activation transforms Ras into an oncogenic form, as
demonstrated by the substitution of glycine by valine at codon 12
in Harvey (H)-Ras (H-Ras
val 12), results in the loss of intrinsic
GTPase function and therefore the protein is constitutively in the
active, GTP-bound state and is continuously sending signals for
cell growth (Rayter et al, 1989; Maculuso et al, 2002). Statistics
reveal that 10–25% of all human malignancies in clinics were
found to harbour a variety of Ras mutations (Barbacid, 1987; Bos,
1989), making Ras one of the most important targets to suppress
tumour cell growth (Rinker-Schaeffer et al, 1993; Prendergast et al,
1996).
According to the recent surveys of the WHO (www.who.int/
cancer/resources/incidences/en/), bladder cancer is rated within
the five most common cancers in males in North America,
Northern and Western Europe, and other developed countries.
Transitional cell carcinoma (TCC) is a tumour that occurs mostly
in the urinary bladder and has been linked to multiple and
accumulated aberrations in oncogenes (e.g. H-ras mutations) and
cancer-suppressor genes (e.g. p53 inactivation), as well as to the
allelic loss of specific chromosomal loci (e.g. chromosomes 9q and
11p) (Habuchi et al, 1993; Linnenbach et al, 1993; Brandau and
Bohle, 2001). Mutational activation of the H-ras oncogene was first
reported (Reddy et al, 1982; Tabin et al, 1982) in human T24 TCC
cell line that played an essential role in urothelial carcinogenesis.
Molecular epidemiological studies conducted within different
geographic regions or in different races and tumour stages/grades
have revealed that up to 84% of bladder TCC carried activated H-
Ras (Fontana et al, 1996; Hong et al, 1996; Vageli et al, 1996; Yu
et al, 1996; Saito et al, 1997; Olderoy et al, 1998; Przybojewska et al,
2000). Therefore, oncogenic activation of H-Ras is an important
tumorigenic factor for bladder tumours.
High soybean food consumption, which provides ingestion of a
substantial amount of genistein, has been suggested to contribute
to the relatively low rates of many cancers in Asian countries (Lee
et al, 1991; Messina et al, 1994). Genistein, an isoflavone with a
structure similar to oestrogen (a phyto-oestrogen), possesses
potent inhibitory activities against growth factor-associated
tyrosine protein kinases (Akiyama et al, 1987) and DNA
topoisomerase II (Markovits et al, 1989). It is also an antioxidant
(Naim et al, 1976) with the capability of suppressing angiogenesis
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sand endothelial cell proliferation in vitro (Fotsis et al, 1993).
Genistein is a compound with a variety of potential properties that
mainly inhibit tumour growth in vitro and in vivo. In the mid-
1990s, genistein was used for the first time to treat and
efficaciously inhibit the growth of human bladder tumour cell
lines (Lu et al, 1996). In subsequent experiments with bladder cell
lines derived from superficial (RT4 cells) and invasive (T24 cells)
tumour stages that had been transfected with the different genes to
express the diverse expression levels of H-Ras and epidermal
growth factor receptor (EGFR), this membrane protein has also
been associated with tumorigenesis and is frequently clinically
detected in bladder tumours (Dangles et al, 1997). Genistein and
tyrphostin (an EGFR inhibitor) were both found to preferentially
inhibit the motility and growth of bladder carcinoma cell lines that
overexpressed EGFR (Theodorescu et al, 1998). Cancerous cells
that harboured only mutated Ras but not overexpressed EGFR
were less susceptible to inhibition by these drugs. The authors
(Theodorescu et al, 1998) thus concluded that the upregulation of
EGFR expression, but not oncogenic H-Ras, played a key role in
developing tumour-invasive phenotype in T24 cells. In animal
model studies, genistein has been consistently demonstrated to
reverse the cancerous phenotype of mouse fibroblast (NIH3T3)
cells transformed by v-H-Ras or H-Ras
val 12 (Okura et al, 1988; Kuo
et al, 1994). Zhou et al (1998) reported an in-depth study of the
inhibitory effects of genistein on bladder tumorigenesis with both
murine and human cell lines and in a mouse animal model (Zhou
et al, 1998). The result of the study demonstrated that the
compound inhibited the growth of two mouse and three human
bladder cell lines, in a dose-dependent fashion, via cell cycle arrest
at the G2/M phase and/or apoptosis. Importantly, mouse tumours
derived from the transplantation of murine bladder cancer cells
also responded to the inhibitory effects of genistein. A similar
report (Su et al, 2000) published 2 years later also confirmed that
genistein induced cell cycle arrest and inhibited CDC2 kinase
activity that suppressed bladder tumour cell growth. These data
suggest that the drug has potent anticancer effects both in vitro
and in vivo, and, therefore, genistein has become one of the
potential therapeutic compounds to treat patients with urinary
bladder neoplasms.
Our research (Chen et al, 2001; Shieh and Li, 2004) has focused
on gene expression alterations in human bladder tumour cells
induced by genistein, in the hope to gain insight into the molecular
mechanism(s) of growth inhibition mediated by this drug, and the
identification of potential genes that may be further evaluated for
possible therapeutic application. Herein, we demonstrate that
among eight human bladder tumour cell lines (5637 (Fogh, 1978),
BFTC905 (Tzeng et al, 1996), HT1197 (Rasheed et al, 1977), J82
(O’Toole et al, 1978), SCaBER (Cheng et al, 1995), T24 (Reddy et al,
1982; Tabin et al, 1982), TSGH-8301 (Yeh et al, 1988), and TCCSUP
(Nayak et al, 1977)) tested for the susceptibility of genistein-
induced growth inhibition, only the activated H-ras-harbouring
T24 cells were consistently resistant to this drug treatment. From
this investigation, we concluded that the H-Ras
val 12-induced signal
transduction pathway was mainly responsible for the resistant
phenotype of T24 bladder TCC cells to the anticancer drug.
MATERIALS AND METHODS
Materials, cell cultures, and cell proliferation assay
Molecular biology enzymes and reagents were purchased from
Stratagene (La Jolla, CA, USA) unless otherwise specified. Standard
chemicals and reagents were obtained from Sigma (St Louis, MO,
USA). All reagents were used according to the recommendations of
the manufacturers. Eight bladder tumour cell lines, including 5637,
BFTC905, HT1197, J82, SCaBER, T24, TSGH-8301, and TCCSUP,
were all maintained in DMEM supplemented with 10% foetal
bovine serum, 100Uml
 1 penicillin, and 100mgml
 1 streptomycin
(these tissue cultural reagents were from Gibco, Grand Island, NY,
USA) under 5% CO2 at 371C. Primary bladder epithelial cells
(BDEC) were obtained from BioWhittaker (San Diego, CA, USA)
and maintained as recommended by the supplier. Cell proliferation
assay with a tetrazolium compound and phenazine ethosulphate
(CellTiter 96
s AQueous One Solution Cell Proliferation Kit,
Promega; Madison, WI, USA) was used to analyse the growth-
inhibitory effect of genistein (Sigma) according to the protocol
reported previously (Chen et al, 2001). Each 5000 bladder primary
or tumour cells were seeded into wells of 96-well culture plates,
followed by addition of genistein in the concentrations indicated in
Figure 1. The cells were incubated for 72h before applying the cell
proliferation assays. The genistein stock solution (50mM) was
prepared with pure DMSO (Sigma) and was later diluted to the
appropriate concentrations with DMEM at the time of use.
cDNA microarray and antisense experiments
The experiments of profiling gene expression patterns in different
bladder tumour cells treated with 50mM genistein were routinely
performed by using self-produced cDNA microarrays and a
hybridisation/detection protocol (Chen et al, 2001; Shieh and Li,
2004; w3.csmu.edu.tw/~chingli-Biochip/). Here, we showed the
changes of egr-1 and c-fos expression levels in T24 and TSGH-8301
cells with respect to the time of induction.
Several high-quality phosphorothioate oligodeoxynucleotides
(ODNs) were synthesised (MDBio Inc.; Taipei, Taiwan, ROC) to
block the synthesis of the target gene products. All these ODNs
contained 14 phosphorothioate groups to ensure the best stability
during transfection, as demonstrated by the anti-H-ras expression
experiments reported previously (Monia et al, 1996). Except for
the VDUP-1 gene (Han et al, 2003), we used the previously
reported, as listed below, antisense and control ODNs
in experiments targeted to the expressions of H-ras,c -fos,o r
egr-1 gene. They include anti-oncogenic-H-ras antisense and
controls (antisense, 50-CsCsAsCsAsCsCsGACsGsGsCsGsCsCsC-30;
control, 50-GsAsGsCsTsCsCsCAGsGsCsTsCsAsGsA-30) (Chen et al,
1996; Monia et al, 1996), anti-c-fos antisense and mutated
(antisense, 50-GsAsAsGsCsCsCsGAGAsAsCsAsTsCsAsT-30; mu-
tated, 50-GsAsAsGsTsCsCsAAGGsAsCsGsTsCsAsT-30, with the
underlined nucleotides representing as substitutions) (Gibellini
et al, 1997), anti-egr-1 antisense and scrambled (antisense,
50-TsGsCsGsGsGsGsCGCGGGsGsAsAsCsAsCsT-30; scrambled, 50-
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Figure 1 The susceptibilities of bladder TCC cell lines and BDEC to
growth inhibition by genistein. The growth inhibition curves for BDEC and
eight human bladder TCC cell lines are illustrated. To prevent confusion
caused by drawing nine curves with error bars in a small plot, we divided
the studied cell lines into three groups (panels A–C) according to their
relative growth rates in the presence of increasing genistein concentrations.
Panel A: insensitive cell lines include T24 (,) and primary bladder epithelial
cells (&). Panel B: 5637 (,), BFTC905 (&), HT1197 (J), and J82 (n)
were cell lines that were moderately inhibited. Panel C: relative sensitive
cell lines include SCaBER (n), TCCSUP (,), and TSGH-8301 (&). These
experiments were performed twice with duplicate samples.
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sGsTsCsGsCsAsCsGCGTGCsGsAsGsGsAsGsG-30) (Sells et al, 1995),
and anti-VDUP-1 gene antisense and sense (antisense,
50-TsTsCsTsTGAACATCAsCsCsAsT-30; sense, 50-AsTsGsGsTGAT
GTTCAsAsGsAsA-30) ODNs, where an ‘s’ indicates a phosphor-
othioate-capped moiety and they were used in cell proliferation
assays or immunoblotting experiments. Approximately 6000
appropriate cells were seeded in the wells of a 96-well flat-bottom
microtitre plate, followed by adding indicated amounts of an ODN
premixed with ESCORT transfection reagent (used according to
the instruction provided by Sigma) and incubating in a CO2
incubator for 8h at 371C. The cells were further treated with 50mM
genistein for another 72h before they were subjected to cell
proliferation assays. As the controls for T24 cell proliferation
assays under various conditions, BDEC and TCCSUP cells were
also grown and passed through the identical procedure in parallel.
Reverse transcription–polymerase chain reaction and
immunoblotting analyses
The expression levels of egr-1 and c-fos in TSGH-8301 and T24
cells treated without or with 50mM genistein for the various time
points were determined by semiquantitative reverse transcrip-
tion–polymerase chain reaction (RT–PCR). The amplification
primers used were: (1) b-actin: forward 50-ATCATGTTTGA
GACCTTCAA-30 and reverse 50-CATCTCTTGCTCGAAGTCCA-30;
(2) egr-1: forward 50-CTGCACGCTTCTCAGTGTTC-30 and reverse
50-AGCAGCATCATCTCCTCCAG-30; and (3) c-fos: forward 50-AAG
GAGAATCCGAAGGGAAA-30 and reverse 30-GCTGCTGATGCT
CTTGACAG-30. The RT–PCR of these genes was performed at
the cycles that the amplification of DNA molecules was in the
exponential increasing stage. After many tests to correlate with the
PCR product amounts and thermocycling numbers (data not
shown), we used 20 amplification cycles for b-actin and 27 cycles
for both egr-1 and c-fos genes. The RT–PCR products were
visualised by agarose gel electrophoresis in the presence of
ethidium bromide.
When performing Western blot analyses with ODN-treated cells,
5 10
6 cells were placed in a six-well culture plate, followed by
treating with ODNs, 5mM each time, and the same amount of
genistein, as in the protocol described above. After incubation and
removal of culture supernatants, 50ml of RIPA lysis buffer
(Helfrich et al, 1994) was used to lyse and then collect cell extracts
for SDS–PAGE. The entire immunoblotting procedure employed a
commercial standardised technique (BM Chemiluminescence
Western Blotting Kit, Roche Applied Science; Mannheim, Ger-
many) with rabbit antibodies against human H-Ras (clone C-20),
c-Fos (4), and Egr-1 (588) proteins that were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Chemilumines-
cent detections of antibody–antigen complexes revealed the target
proteins on X-ray film. The cell proliferation assays and Western
blotting experiments were all performed in triplicate and identical
results were obtained.
RESULTS
The effect of genistein on bladder tumour cell growth and
gene expression
In order to extend our previous efforts to gain insights into the
molecular mechanism for genistein-induced cell growth inhibition
in bladder tumour cells (Chen et al, 2001; Shieh and Li, 2004), we
tested the effect of the drug on eight bladder tumour cell lines
(including 5637, BFTC905, HT1197, J82, SCaBER, T24, TSGH-8301,
and TCCSUP) and BDEC. We divided the cell lines into three
groups depending on their susceptibilities to the growth-inhibitory
effect of genistein: T24 cell line and BDEC were relatively
insensitive to the drug treatments that consistently maintained
the growth rate above 75% of the respective mock-treated cells
when the highest concentration (50mM) of the drug was used
(Figure 1A); cell lines HT1197, HT1376, J82, BFTC905, and 5637
moderately reduced their growth rates to 65–55% (Figure 1B); and
SCaBER, TSGH-8301, and TCCSUP cells were always susceptible to
the drug treatments as their growth rates were dramatically
reduced to 30–35% at the genistein concentration of 50mM.W e
also found that the J82 cell line had elevated growth rates at low
genistein concentrations (Figure 1B), which might be due to the
stimulatory effect of DMSO solvent (10%), a similar effect had
been observed with HepG2 and Hep3B hepatocellular carcinoma
cell lines (Li, unpublished data), and therefore the growth-
inhibitory effect could be detected only when the highest
concentration of genistein (50mM) was used. Since BDEC was not
a tumour cell line but was regarded as the normal cell control, the
growth should not be greatly inhibited by the anticancer drug, and
indeed, the growth rates were only slightly reduced and then
maintained close to 80% at concentrations equal to or greater than
20mM (Figure 1A). The cell proliferation assays demonstrated that
T24 was the only TCC cell line that consistently resisted genistein,
and the growth rates were always maintained at 90–95% during
the drug treatments. Although the degree of the inhibition varied
among cell lines, this result basically agreed with the previous
results reported by Zhou et al (1998).
In the previous experiments, we used a self-made Millennia-
Chip, version 1 cDNA microarrays to profile differential gene
expression patterns in genistein-stimulated TCCSUP, TSGH-8301,
and T24 bladder TCC cell lines (Chen et al, 2001; Shieh and Li,
2004). The most notable finding in these studies was the dramatic
difference in the expression patterns of two immediate early genes
egr-1 and c-fos. In the genistein-sensitive cell lines, TCCSUP and
TSGH-8301, the genes revealed transient and inducible kinetics
which peaked at 0.5h post treatment of genistein just as were
reported in many physiological conditions (Liu et al, 1991),
whereas in genistein-resistant T24 cells both genes were constitu-
tively expressed but could be induced to the higher levels by the
drug, followed by declining to the lower levels. Figure 2A
demonstrates the expression levels of egr-1 and c-fos in TSGH-
8301 and T24 cells derived from cDNA microarray analyses,
whereas Figure 2B confirms such gene expression profiles with
RT–PCR. Since the overexpression of oncogenic H-Ras
val 12 has
only been reported in T24 cells, we speculated that the oncoprotein
stimulated the coincidental abnormal egr-1 and c-fos expression
patterns in the cells, as reported previously (Stacey et al, 1987;
Alexandropoulos et al, 1992). Therefore, we investigated the role of
H-Ras
val 12 in mediating cellular signal transduction pathway in
T24 tumour cell line that rendered the resistant phenotype against
the growth-inhibition effect of genistein.
In vitro targeting gene expressions and the susceptibility to
genistein inhibition
Since the most prominent signal transduction pathway regulated
by Ras is Raf-1-mediated signalling which results in c-Fos
induction (Maruta and Burgess, 1994), we examined the effect of
H-Ras
val 12 or c-Fos expression on the susceptibility of T24 cells to
genistein inhibition. Antisense phosphorothioate ODNs targeted to
the expression of either gene was used to treat T24 cells, followed
by assaying the cell proliferation rate in the presence of 50mM
genistein. The experiments detected that the levels of H-Ras
val 12
were moderately reduced in the cells treated with 5mM of control
ODN for 2h (Figure 3A, lanes 5 and 6 vs lanes 1 and 2,
respectively), whereas the levels fell dramatically to one-third or
lower of the original level if the same amount of the anti-H-ras
ODN was used for the same period of time (Figure 3A, lanes 3 and
4 vs lanes 1 and 2, respectively), as determined by immunoblotting.
After 72h incubation, the effect of anti-H-ras ODN on blocking H-
Ras
val 12 synthesis was even more obvious (lanes 8 and 9 vs lanes
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s10 and 11, respectively). In all studies, the presence or absence of
genistein did not affect the expression of H-Ras greatly or yielded
inconsistent expression levels (odd vs even samples in lanes 1–6
and also in lanes 8–11). Since the anti-H-ras ODN could effectively
block the gene expression level, H-Ras
val 12 downregulated T24
cells that were subsequently subjected to the cell proliferation
assay. Figure 3B reveals that when the various amounts of the
control ODN were used, the growth rates of T24 cell line only
decreased slightly regardless of whether genistein is present or
absent, whereas the cell growth rate is moderately reduced (to 60%
of untreated cells) when the cells are no longer overexpressing
oncogenic H-Ras
val 12 (at 5mM anti-H-ras ODN concentration).
Upon treatment of the cells with both anti-H-ras ODN and 50mM
genistein in cell culture, the T24 cell growth rate was further
decreased to the level (about 35%) that was comparable to the rates
of the genistein-sensitive bladder TCC cell lines, SCaBER, TSGH-
8301, and TCCSUP (Figure 1C). The specificity of the growth
inhibition by antisense ODN was further fortified by using a
mutated anti-H-ras ODN (50-CsCsGsCsAsCsCsGTCsGsGsAs
GsCsCsC-30, with the underlined nucleotides representing sub-
stitutions) (Monia et al, 1996) to treat T24 cells. In this experiment,
the growth rates were similar to those treated with control ODN in
the presence or absence of genistein (data not shown). The result
of this antisense experiment indicates that, without H-Ras
val 12
overexpression, T24 cells become susceptible to the growth
inhibition mediated by genistein.
It is well known that c-Fos is the downstream effector gene of
Ras, and any signal transducing through the Ras/Raf-1 signalling
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Figure 2 Different expression patterns of egr-1 and c-fos in T24 and
TSGH-8301 cells. (A) Treatment of T24 and TSGH-8301 cell lines with
50mM genistein for the indicated periods of time revealed different kinetic
patterns for egr-1 and c-fos expressions (the scale on x-axis is not in
proportion with time). The expression levels for genes, as presented by
arbitrary digitalised intensity, were derived from experiments with cDNA
microarrays and the subsequent quantification of hybridisation signals
according to the protocol described previously (Chen et al, 2001; Shieh and
Li, 2004). In drug-sensitive TSGH-8301 cells, the basal expressions of egr-1
(m) and c-fos (K) were minimal, but were induced acutely and transiently
after stimulation with genistein. On the contrary, in T24 cells, the genes for
Egr-1 (n) and c-Fos (J) were highly expressed without stimulation, but
could be further induced after treatment with genistein, followed by acute
decreases to low levels. These experiments were performed in triplicate.
(B) The expression patterns of both genes have also been confirmed by
using RT–PCR with RNA samples from TSGH-8301 and T24 cells
stimulated by genistein for 0–12h. Similar to the microarray experiments,
TSGU-8301 cells did not express either egr-1 or c-fos without genistein
treatment, whereas T24 cells constitutively expressed these two genes. At
0.5h post induction with the drug, the expression levels of both genes
were upregulated to the highest levels, followed by linear reduction to the
levels close to the original production ratio at 12h. The size of the egr-1,c -
fos, and b-actin PCR DNA fragments are 260, 373, and 318bp,
respectively. These experiments were performed in duplicate.
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Figure 3 Influence of H-Ras
val 12 ovexpression on the growth of T24
cells responding to antisense oligonucleotide and genistein treatments. (A)
T24 cells were treated with 5mM of the indicated phosphorothioate ODN
alone or the ODN and 50mM genistein, followed by cell extract isolation
and Western blotting with the anti-H-Ras antibody. The intensities of H-
Ras
val 12 protein were quantified with a densitometer, and the Ratio line
revealed the percentage of the protein produced (after normalising with
the levels of actin protein) in the ODN or/and genistein-treated cells vs
untreated T24 cells. The result revealed that the expression of H-Ras
val 12
was inhibited to a greater degree by treating with the antisense ODN than
with the control ODN or genistein, and the effect was strikingly obvious
after 72h incubation. Under all experimental conditions, actin remained
relatively unchanged. The control ODN was a 17-mer targeted to human
immunodeficiency virus, which was used in parallel with anti-H-ras
val 12
ODN, as described previously (Chen et al, 1996). (B) With increasing
amounts of different ODNs, the growth rates of T24 cell line were
determined in the presence or the absence of 50mM genistein. The plot
reveals that only when the anti-H-ras, but not control, ODN (5mM)i s
added, the growth of T24 cells is inhibited in the absence of genistein and
the growth rate is further reduced to below 40% of the untreated cells
when the drug is added, suggesting that the expression of H-Ras renders
drug-resistant phenotype. The symbols used are: cells without any
treatment, &; and cells treated with 0.5% DMSO solvent, ’;5 0 mM
genistein, ; the control ODN, ; the control ODN supplemented with
50mM genistein, ; the anti-H-ras antisense ODN, ; and the antisense
ODN plus genistein, .
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spathway results in nuclear induction of c-Fos, a subunit of the
transcription factor AP-1. We intended to test the drug sensitivity
of T24 cells when the c-fos expression had been retarded in vivo by
treating with the ODN that has been reported to be effective in
blocking cellular c-Fos expression (Gibellini et al, 1997). We
detected that when 5mM anti-c-fos ODN was added to T24 cells, the
levels of c-fos were dramatically decreased to half of the detected
level in untreated cells at all time points (Figure 4A, lane 1 vs other
lanes), and the drug-resistant phenotype of T24 cells was reversed
(Figure 4B). In these experiments, we used a mutant anti-c-fos
ODN, as a negative control, because it contained a sequence like
the anit-c-fos ODN, but with four dispersed nucleotide substitu-
tions that could interrupt the specific binding to its target c-fos and
lost inhibitory capability. The use of the mutated ODN can thus
demonstrate the specificity of antisense oligonucleotide in block-
ing the expression of c-Fos. As detected in Figure 4, the mutant
anti-c-fos ODN and genistein together inhibited cell growth
moderately (to about 60%), whereas 5mM anti-c-fos ODN alone
was able to reduce T24 cell growth rate to 40% of the mock-treated
cells, which might be due to the efficient inhibition of c-Fos
expression and activity that led to reduction in the growth rate.
The growth rate of the T24 cell line was further decreased to 15%
when both anti-c-fos ODN and genistein were employed simulta-
neously. Similar results were also observed when 10mM of all ODNs
was used to treat cells under identical conditions (data not shown),
suggesting that the correlation between the treatment with
antisense or mutated ODN and the drug-resistant phenotype of
T24 cells is specific. We thus concluded that c-Fos expression also
influenced the drug susceptibility of T24 cells, just as its upstream
regulator H-Ras
val 12. Although Ras and c-Fos are in the same
pathway, the inhibitory effect of c-fos ODN was greater than that of
ras ODN, which may be represented by the differential efficiency of
individual ODNs on inhibiting their targets, and that frequently
depends on the nature and/or nucleotide sequences of the
molecules.
The specificity of the above antisense experiments was further
investigated. From the previous microarray hybridisation experi-
ments, the egr-1 and VDUP-1 gene expressions were known to be
significantly induced by genistein in TCCSUP and TSGH-8301 cells
(Chen et al, 2001; Shieh and Li, 2004), and the former gene was
constitutively overexpressed in T24 cells (Figure 2). Since
alterations in gene expression patterns frequently indicate the
involvement of the gene products in the biological/pathological
processes of interest, we examined the role of egr-1 or VDUP-1 in
the resistance of T24 cells to genistein, and the results were
compared to those from the antisense ODN experiments (Figures 3
and 4) studying the functions of H-Ras
val 12 and c-Fos. Our
experiments detected that, regardless of the egr-1 antisense or the
scrambled control ODN used in cell cultures, the drug sensitivities
of T24 cells remained unchanged, and the same results were also
obtained from experiments using antisense or sense ODN targeted
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Figure 4 Influence of c-fos expression on the growth of T24 cells
responding to antisense ODN and genistein treatments. (A) The level of c-
Fos was highly expressed in mock-treated cells (lane 1), whereas the c-Fos
protein level was greatly reduced 1h after the anti-c-fos ODN (5mM) was
added and the suppression lasted for several hours (lanes 2–5). The ratio
line indicates the percentage of the protein produced in the ODN or/and
genistein-treated cells vs untreated T24 cells. Under all experimental
conditions, the levels of actin protein remained unchanged. (B) This plot
demonstrates that the growth of T24 cells is not inhibited when adding the
mutated ODN up to the concentration of 5mM, but the growth rates are
greatly decreased, to essentially 40% of the mock-treated cells, when the
same amount of the anti-c-fos ODN is present in cell cultures. Adding
50mM genistein to T24 cells pre-treated with 5mM mutated ODN affected
the growth rate moderately (to about 60%), but the cells almost ceased to
grow (to 10–15%) as the antisense ODN treatments (5mM) were
combined with genistein. As an increased amount of the ODNs (10mM)
was applied to the identical experiments described above, a similar result
was obtained (data not shown). The symbols used here are: cells without
any treatment, &; and cells treated with 0.5% DMSO, ’;5 0mM genistein,
; the mutated ODN, ; the mutated ODN supplemented with 50mM
genistein, ; the anti-c-fos antisense ODN, ; and the antisense ODN plus
genistein, .
120
100
80
60
40
20
0 0 0.1 1.0 5.0
Anti-egr-1 Anti-VDUP-1 gene
ODN concentration (M)
C
e
l
l
 
g
r
o
w
t
h
 
r
a
t
e
 
(
%
)
10.0 1.0 5.0 10.0
Figure 5 Suppression of egr-1 or the VDUP-1 gene expression did not
affect the growth of T24 cells treated with genistein. Since the expression
of the egr-1 and VDUP-1 genes was dramatically induced by genistein in T24
cells, their role in reversing the inhibitory effect of the drug was investigated.
The effect of blocking gene expression by the antisense and their control
ODNs was tested with Western blotting, and expected results were
obtained (data not shown). The result of cell proliferation assays revealed
that, regardless of the presence and absence of 50mM genistein, treatment
of the T24 cell line with the antisense ODN for either gene (up to 10mM),
did not alter the cell growth pattern, suggesting that these proteins are not
involved in the drug resistance mechanism. In these experiments, the
nucleotide sequence-scrambled egr-1 ODN, which had been characterised
previously (Sells et al, 1995) and the sense-strand ODN for the VDUP-1
genes, which is according to the reported gene sequence (Han et al, 2003),
were used as controls. The result demonstrated that they did not have any
influence on the growth of T24 cells even when genistein was added. The
symbols used here are: cells without any treatment, &; and cells treated
with 0.5% DMSO, ’;5 0mM genistein, ; the control ODN for egr-1 or the
VDUP-1 gene, ; the control ODN for egr-1 or the VDUP-1 gene
supplemented with 50mM genistein, ; the antisense ODN for either one
gene, ; and the antisense ODN for either one gene plus genistein, .
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sto the expression of the VDUP-1 gene (Figure 5). These data
suggest that the influence of H-Ras or c-Fos downmodulation on
the drug susceptibility of T24 cells was specific. We therefore
concluded that the resistance of T24 cells to the genistein growth-
inhibitory effect must involve the H-Ras
val 12/c-Fos-mediated
signal transduction pathway.
Influence of the functions of proteins kinases on the
growth of T24 cells
The ras gene product regulates a number of discrete intracellular
pathways through its different downstream effectors such as Raf-1,
RalGDS, and PI3K (Maruta and Burgess, 1994; Ramirez et al,
2002), and probably crosstalks to the JNK activation pathway (de
Ruiter et al, 2000). To confirm the H-Ras activation in T24 cells
rendered resistant to the anticancer drug genistein, protein kinase
inhibitors were used to dissect Ras-regulated signal transduction
pathways. First, PD58059 and U0126 were employed to inhibit the
signal transduced from H-Ras to c-Fos by blocking the kinase
functions of MEK and ERK. Figure 6A shows that T24 cells became
genistein-sensitive as the growth rates were significantly decreased
when 50mM genistein and either PD58059 (20mM) or U0126 (10mM)
are present (both Po0.05 by t-test, two-tailed), and both
inhibitory effects were in a dose-dependent manner. This result
was completely in agreement with the previous (Figures 3 and 4)
antisense experiments with the anti-H-ras and anti-c-fos ODNs.
Protein kinase inhibitors H7 and LY294002, which block the
signalling pathways associated to PKC and PI3K, respectively,
were also used in T24 cell proliferation assays with and without the
presence of 50mM genistein. We detected that, at H7 concentration
equal to 10mM or greater, the growth rates of T24 cells were
decreased regardless of the presence or absence of the drug,
suggesting that H7 did not influence the drug susceptibility, and
the cytotoxicity was responsible for cell quiescence at the higher
H7 concentrations (Figure 6B). The inhibitor LY294002 at the
effective concentration of 20mM could only slightly reduce the T24
cell growth rate from 95 to 75% of the mock-treated cells in the
presence and absence of genistein. The results rule out the
involvement of the PKC or PI3K signal transduction pathway in
the drug resistance of the T24 cells.
The Ras pathway is known to interact with the JNK pathway, as
the Ras downstream effector c-Fos forms the transcription factor
AP-1 with c-Jun, a nuclear protein regulated by the function of JNK
(de Ruiter et al, 2000). Owing to this, we investigated the role of
JNK in the susceptibility of T24 cells to genistein. Figure 6C
demonstrates that the JNK inhibitor SP600125 itself exhibits a mild
dose-dependent inhibitory effect on T24 cell growth, and the
addition of 50mM genistein potentiates the growth suppression
further down to the significant lower level, about 50% of the mock-
treated cells, at a concentration of 30mM SP600125 used (Po0.05
by t-test, two-tailed), and the level is similar to that by 20mM
PD98059 or 10mM U0126 as demonstrated in Figure 6A. Since the
JNK inhibitor alone only partly inhibited cell growth, dual protein
kinase inhibitors were tested. The dose-dependent growth inhibi-
tion was again observed if both inhibitors of the H-Ras (U0126)
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Figure 6 Suppression of T24 cell growth with protein kinase inhibitors
and genistein. (A) When 50mM genistein and either PD98059 or U0126
were applied to T24 cells simultaneously, the cell growth rates were
reduced in a dose-dependent manner. The difference reached a
significance level at 20mM PD98059 (marked by *) or 10mM U0126
(marked by **), as compared to that of the cells treated only with the
respective inhibitor without genistein (both Po0.05 by t-test). (B) Other
protein kinase inhibitors such as H7 (PKC inhibitor) and LY294002 (PI3K
inhibitor) did not reverse the T24 drug resistance phenotype but exhibited
only cytotoxicity, as H7 or LY294002 alone could also reduce cell growth
rates to the levels similar to the cell cultures simultaneously treated with the
inhibitors and the drug at the high concentrations. (C) Adding JNK inhibitor
SP600125 to T24 cells rendered the dose-dependent growth suppression
in the presence of genistein. Statistical analysis (t-test) revealed that the
reduction of the cell growth rate reached significance (Po0.05) only when
genistein was added to T24 cells that were previously treated with 30mM
SP600125 (*) as compared to that of the cells treated only with SP600125.
The dose-dependent suppression of cell growth was even more substantial
when inhibitors for both JNK, at the concentrations of 10, 20, or 30mM, and
MEK/ERK (U0126) were simultaneously added to T24 cell cultures, as
compared to those cells treated only with 10, 20, or 30mM SP600125,
respectively (all Po0.05 and indicated by **). Furthermore, comparing the
growth rates of T24 cells pretreated only with 10mM U0126 and the
indicated amounts of SP600125, the rates were again significantly reduced
when the anticancer drug was simultaneously applied (all Po0.05 and
indicated by ***). In this experiment, the growth rate reached levels
comparable to those of the genistein-sensitive cell lines. The symbols used
in all panels are: cells without any treatment, &; and cells treated with 0.5%
DMSO, ’;5 0mM genistein only, ; cells only treated with protein kinase
inhibitor(s), ; cells treated with both protein kinase inhibitor(s) and
genistein, .
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sand JNK (SP600125) signalling pathways were used together. As
illustrated in Figure 6C, treatment of T24 cells with 10mM U1026
and increasing amounts of SP600125 (10–30mM) renders the
decreasing T24 cell growth rates down to 50% of untreated cells
(all reached significant levels at Po0.05). Under identical culture
condition, addition of genistein further inhibited the growth rates
significantly to approximately 20% of the original growth rate (all
Po0.05), which was comparable to those of the genistein-sensitive
bladder TCC cell lines (Figure 1). These data suggest that signal
transduction through the JNK pathway is also involved in the
resistance of T24 cells to genistein.
DISCUSSION
In this study, we employed microarray technology, antisense
oligonucleotide inhibition, and cell proliferation assays to identify
and characterise genes that are playing key roles in the resistance
of T24 bladder TCC cell lines to the anticancer drug genistein.
Genistein is a phyto-oestrogen that is present in high quantity in
many traditional Asian diets containing soybean products
(Messina et al, 1994). The compound is regarded as a potential
and ideal anticancer drug to treat patients with bladder tumours,
because the compound is a natural product present in diet that has
been proven to be effective in treatment of bladder TCC (Zhou
et al, 1998; Su et al, 2000), as well as safe with minimal side effects
and inexpensive. In 1996, the compound was subjected to the
clinical chemoprevention trials for preventing breast cancer and
acute lymphoblastic leukaemia (Quella et al, 2000; Wang, 2000).
Although genistein has shown some promising cancer cell growth-
inhibitory effects, many concerns, such as which function(s) is
(are) actually playing an essential role in tumour suppression or
does it involve the induction of gene expression, remain to be
determined. We therefore rationalised that a functional genomic
study of genistein-induced gene expression alternation would be
the most effective and also the most rapid means to identify the
key gene(s) involving the cell growth regulatory pathway.
The anticancer effect of genistein has been mostly studied in
breast tumours at the molecular level (El-Deiry et al, 1993; Harper
et al, 1993), and the regulatory event was independent of the
oestrogen receptor and the cancer suppressor p53 protein (Li et al,
1999; Xu and Loo, 2001). Bladder TCC has been shown to undergo
apoptosis induced by genistein through the EGFR signalling
pathway involving p21
WAF1/CIP1 expression (Dangles et al, 1997). It
has also been demonstrated that genistein exhibited dose-
dependent (0–50mM) growth inhibition of many murine and
human bladder cancer cell lines, providing evidence of cell growth
arrest at the G2/M phase followed by apoptosis in some cell lines
(Zhou et al, 1998). In this study, we focused on the genistein
growth inhibition of only human cell lines, and compared different
gene expression patterns in human cell lines sensitive and resistant
to the genistein treatments with cDNA microarrays. From the
results, we are convinced that the overexpression of oncogenic H-
Ras
val 12 and its control of the signal transduction pathway were
solely responsible for the resistance of the T24 bladder TCC cell
line to genistein growth inhibition. It is possible that genistein
inhibits the growth signals from the tyrosine protein kinase-
associated receptors, such as EGFR and PDGFR (platelet-derived
growth factor receptor), to small G protein Ras and thus
suppresses cell growth, just like the inhibitory model proposed
for genistein prevention of phenylephrine-induced Ras activation
(Thorburn and Thorburn, 1994). In such a situation, T24
H-Ras
val 12, which is downstream from the action site of
genistein, constantly sends very strong cellular proliferative
signals, resulting in the drug-resistant phenotype. H-Ras
val 12
is also responsible for maintaining the fast growth rate of T24
cells in routine tissue cultural experiments, and blocking the
protein or c-Fos synthesis with antisense OND or interrupting
the function of Ras downstream protein kinases by inhibitors
frequently resulted in decreasing the growth rate, as we observed
in many of our cell proliferation experiments (Figures 3B, 4B,
and 6C). However, it is still unclear why other TCC cell lines such
as TCCSUP and TSGH-8301 could be induced to transiently
express c-Fos but remained susceptible to the inhibitory effect of
genistein. Furthermore, our finding that the overexpression of the
H-ras oncogene counteracts the anticancer effect of genistein in
T24 cells is contrary to previous reports demonstrating that the
drug was capable of (1) reversing the malignant phenotypes of
mouse fibroblast (NIH3T3) cells transformed by v-H-Ras or H-
Ras
val 12 (Okura et al, 1988; Kuo et al, 1994; Li, unpublished data)
and (2) suppressing the Ras activity induced by phenylephrine in
neonatal rat ventricular myocytes (Thorburn and Thorburn, 1994).
This discrepancy may be due to differences in genetic and
tumorigenic backgrounds, as suggested by a previous report
(Hamad et al, 2002), and, certainly, the clinical behaviour of
human bladder tumours responding to genistein treatment is likely
to more closely resemble that of the T24 cell line which was derived
from human bladder TCC.
In summary, this study provided data of cell proliferation
experiments employing antisense ODNs and protein kinase
inhibitors, which indicate that the resistance of T24 cells to the
genistein growth-inhibitory effect is predominantly due to the
activation of oncogenic H-ras that transduces the growth signal
through the MEK/ERK pathway and interferes with the JNK
signalling pathway.
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